OBJECTIVE: The aim of this study was to identify clinical and pathologic characteristics of
patients with uterine papillary serous carcinoma (UPSC) who were all surgically managed at a …

… B. Slomovitz receives research funding from Genentech/Roche, Novartis, and AstraZeneca.
RL Coleman receives research funding from Genentech/Roche, Merck, Novartis, and …

Objectives. Synchronous primary cancers of the endometrium and ovary are found in 10% of
women with ovarian cancer and 5% of women with endometrial cancer. The purpose of this …

Background Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in
recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-…

Background Dostarlimab is an immune-checkpoint inhibitor that targets the programmed
cell death 1 receptor. The combination of chemotherapy and immunotherapy may have …

Background Women with the Lynch syndrome (hereditary nonpolyposis colorectal cancer)
have a 40 to 60 percent lifetime risk of endometrial cancer and a 10 to 12 percent lifetime risk …

OBJECTIVE: Endometrial cancer is the most common gynecologic malignancy in the United
States. The mean age at diagnosis is 61 years; however, 5–30% of women are aged …

BACKGROUND Obesity is a well known risk factor for the development of endometrial
cancer; however, weight alone does not account for all cases. The authors hypothesized that …

Background Low-grade serous carcinoma of the ovary or peritoneum is characterised by
MAPK pathway aberrations and its reduced sensitivity to chemotherapy relative to high-grade …

BACKGROUND: Dysregulation of phosphatase and tensin homolog (PTEN) and the gene that
encodes the p110α catalytic subunit of phosphatidylinositol‐3‐kinase (PI3K), PIK3CA, are …